Essex Investment Management Co. LLC Has $2.02 Million Position in Evolus, Inc. (NASDAQ:EOLS)

Essex Investment Management Co. LLC decreased its holdings in shares of Evolus, Inc. (NASDAQ:EOLS) by 38.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 182,503 shares of the company’s stock after selling 113,050 shares during the quarter. Essex Investment Management Co. LLC’s holdings in Evolus were worth $2,015,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. KBC Group NV bought a new stake in Evolus during the 4th quarter worth about $49,000. IFP Advisors Inc increased its position in shares of Evolus by 17,440.7% in the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock valued at $52,000 after acquiring an additional 4,709 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Evolus during the third quarter worth about $132,000. China Universal Asset Management Co. Ltd. boosted its position in Evolus by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company’s stock valued at $148,000 after purchasing an additional 1,291 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new position in Evolus in the third quarter valued at approximately $191,000. Institutional investors own 90.69% of the company’s stock.

Evolus Stock Performance

EOLS opened at $13.58 on Monday. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. Evolus, Inc. has a 12-month low of $9.25 and a 12-month high of $17.82. The business has a 50 day moving average of $12.95 and a 200-day moving average of $14.05. The stock has a market cap of $863.51 million, a price-to-earnings ratio of -14.92 and a beta of 1.28.

Analyst Ratings Changes

EOLS has been the topic of a number of analyst reports. Barclays upped their price objective on Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price target on shares of Evolus in a research report on Wednesday, March 5th. Finally, HC Wainwright reiterated a “buy” rating and issued a $27.00 price target on shares of Evolus in a research note on Wednesday, March 5th.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.